Change in MUNIX in Patients With CMT1A Undergoing a Home Ankle Strengthening Program Versus Standard of Care

Inclusion Criteria: * Adult Patients 18 years or older with genetically confirmed CMT1A * Adult Patients 18 years or older with a CMT1A genetically confirmed relative and a positive clinical exam or nerve conduction study consistent with CMT1A. * Unaffected persons 18 years or older with no past medical history of peripheral neuropathy Exclusion Criteria: * Patients with a history of medical diseases that affect peripheral nerve function including diabetic neuropathy, uncontrolled thyroid dysfunction, amyloidosis, monoclonal gammopathy of uncertain significance or untreated vitamin deficiencies. * Patients with a history of other neurologic disease which may affect peripheral nerve function or extremity strength or function including stroke, seizures with a history of Todd's paralysis, Parkinson's Disease, Dementia, Guillen-Barre Syndrome, Myasthenia Gravis, Lambert Eaton Myasthenia Gravis or hypothyroidism. * Patients with ankle dorsiflexion strength of less than 3/5 in either limb on Medical Research Council scale. * Patients enrolled in a clinical trial (excluding natural history studies) in the past 12 months. * Patients who have undergone intense physical therapy, meaning more than 1 time per week for 6 or more weeks within the last 12 months. * Patient who do resistance training of the lower extremity more than 2 times per week for more than 3 months. * Patient in whom exercise would be consider dangerous including autonomic failure, postural orthostatic tachycardic …